Literature DB >> 16003135

Impact of MELD on short-term and long-term outcome following liver transplantation: a European perspective.

Evi Nagler1, Hans Van Vlierberghe, Isabelle Colle, Roberto Troisi, Bernard de Hemptinne.   

Abstract

INTRODUCTION: The Model for End-Stage Liver Disease (MELD) has been found to accurately predict pre-transplant mortality and is a valuable system for ranking patients in need of liver transplantation. Its association with post-transplant outcome, however, remains unclear.
MATERIALS AND METHODS: We retrospectively studied 121 adult patients who were transplanted for non-fulminant liver failure between January 1991 and December 2001. MELD scores were calculated taking variables as close as possible prior to liver transplantation. Patients were stratified into two or three groups using different cut-off values of the MELD score.
RESULTS: Indications for liver transplantation were mainly alcoholic liver disease (47.1%) or hepatitis C virus (19.0%). Gender distribution was male 62% vs female 38%. Mean age was 54 years+/-10 years. Mean MELD score was 16+/-6. Follow-up time was 5.4 years (range, 1.6-12.3 years). The use of different MELD cut-off levels yielded no difference in survival at different time points.
CONCLUSION: Higher MELD scores did not have a negative impact on patient and graft survival following OLT. Since MELD is good at identifying those urgently in need of liver transplantation and high MELD scores do not appear to have an influence on long-term outcome, use of MELD in liver allocation seems warranted.

Entities:  

Mesh:

Year:  2005        PMID: 16003135     DOI: 10.1097/00042737-200508000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

Review 1.  Prioritization for liver transplantation.

Authors:  Evangelos Cholongitas; Giacomo Germani; Andrew K Burroughs
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

2.  Intensive care management of liver transplanted patients.

Authors:  Paolo Feltracco; Stefania Barbieri; Helmut Galligioni; Elisa Michieletto; Cristiana Carollo; Carlo Ori
Journal:  World J Hepatol       Date:  2011-03-27

3.  Application of the BAR score as a predictor of short- and long-term survival in liver transplantation patients.

Authors:  Ivan Dias de Campos Junior; Raquel Silveira Bello Stucchi; Elisabete Yoko Udo; Ilka de Fátima Santana Ferreira Boin
Journal:  Hepatol Int       Date:  2014-08-09       Impact factor: 6.047

Review 4.  Model for end-stage liver disease: end of the first decade.

Authors:  Sumeet K Asrani; W Ray Kim
Journal:  Clin Liver Dis       Date:  2011-10-01       Impact factor: 6.126

5.  [Allocation systems in transplantation medicine: Advantages and disadvantages].

Authors:  J Gottlieb; W Gwinner; C P Strassburg
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

Review 6.  Model for end-stage liver disease score and MELD exceptions: 15 years later.

Authors:  Sumeet K Asrani; Patrick S Kamath
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

7.  Aorto-hepatic bypass in liver transplantation in the MELD-era: outcomes after supraceliac and infrarenal bypasses.

Authors:  Richard Hummel; Sabrina Irmscher; Christina Schleicher; Norbert Senninger; Jens G Brockmann; Heiner H Wolters
Journal:  Surg Today       Date:  2013-03-05       Impact factor: 2.549

Review 8.  [Liver transplantation: indications and results].

Authors:  C P Strassburg; M P Manns
Journal:  Internist (Berl)       Date:  2009-05       Impact factor: 0.743

9.  Historical perspective of living donor liver transplantation.

Authors:  See Ching Chan; Sheung Tat Fan
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

10.  Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.

Authors:  Reham Abdel-Wahab; Manal M Hassan; Bhawana George; Roberto Carmagnani Pestana; Lianchun Xiao; Sahin Lacin; Suayib Yalcin; Ahmed S Shalaby; Humaid O Al-Shamsi; Kanwal Raghav; Robert A Wolff; James C Yao; Lauren Girard; Abedul Haque; Dan G Duda; Simona Dima; Irinel Popescu; Hesham A Elghazaly; Jean-Nicolas Vauthey; Thomas A Aloia; Ching-Wei Tzeng; Yun Shin Chun; Asif Rashid; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb
Journal:  Oncology       Date:  2020-10-07       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.